PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings (NASDAQ:), Inc. today announced… (the Company or Sonnet) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapy drugs, announced the publication of the next installment of CEO Corner on Company website.
As part of the CEO Corner segment, Pankaj Mohan, Ph.D., Founder and CEO of Sonnet, highlighted the company's key milestones for calendar year 2024 and target milestones for value creation in calendar year 2025.
The CEO Corner can now be accessed on the company's website here. The sections on the CEO Corner platform can be accessed on the company's website (www.sonnetbio.com) for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for creating single- and dual-action biologic drugs. Known as FHAB (fully human albumin binding), this technology uses a fully human fragment of a single chain antibody (scFv) that binds to human serum albumin (HSA) and “hikes” it for transport to the target tissue. Sonnet FHAB is designed to specifically target tumor and lymphoid tissues, with an enhanced therapeutic window to improve the safety and efficacy of immunomodulatory biologics. FHAB is a plug-and-play modular building foundation for advancing a range of therapeutic classes of large molecules, including cytokines, peptides, antibodies and vaccines.
Investor Relations Contact:
JTC Team, LLC
Jeanine Thomas
908.824.0775
SONN@jtcir.com
